In a patient with ulcerative colitis on vedolizumab (Entyvio) presenting with hematochezia, alternating constipation and diarrhea, heartburn, nausea, abdominal pain, and vomiting, what interventions and treatment plan should be implemented?

Management of Ulcerative Colitis Flare on Vedolizumab

This patient is experiencing an acute flare of ulcerative colitis despite being on vedolizumab (Entyvio), requiring immediate assessment of disease severity and consideration of treatment escalation or switching to alternative advanced therapy.

Immediate Assessment and Severity Stratification

First, determine if this is an acute severe UC requiring hospitalization or a moderate flare manageable as an outpatient:

• Hospitalize if: ≥6 bloody stools daily with systemic toxicity (fever, tachycardia, anemia, elevated inflammatory markers)
• Outpatient management if: Moderate symptoms without systemic toxicity

The constellation of bloody stool, alternating bowel habits, and GI symptoms (heartburn, nausea, vomiting, abdominal pain) suggests active colonic inflammation, though some symptoms may represent overlapping functional disorders or medication side effects.

Treatment Algorithm Based on Severity

For Hospitalized Acute Severe UC

If hospitalization is required 1:

1. Intravenous methylprednisolone 40-60 mg/day (not higher doses) 1
2. Do NOT add antibiotics unless documented infection 1
3. If steroid-refractory after 3-5 days: Switch to infliximab or cyclosporine 1
   • Infliximab is preferred given vedolizumab failure
   • Consider accelerated dosing regimens

For Outpatient Moderate-Severe Disease

The patient has failed vedolizumab, indicating need for therapy escalation or switch 2:

Primary Options (Based on 2024 AGA Guidelines):

Switch to a different mechanism of action 2:

1. TNF antagonists: Infliximab or golimumab (strong recommendation, moderate-high certainty) 2

   • Infliximab preferred for faster onset
   • Consider combination with immunomodulator (thiopurine/methotrexate) for enhanced efficacy 2, 1

2. JAK inhibitors: Tofacitinib, upadacitinib, or filgotinib 2

   • FDA restriction: Use only after TNF antagonist failure or intolerance 2
   • Since patient failed vedolizumab (non-TNF), technically eligible
   • Faster onset than biologics (response within 2-8 weeks)

3. IL-12/23 inhibitor: Ustekinumab 2

   • Particularly effective after vedolizumab failure 1

4. IL-23 inhibitors: Risankizumab, guselkumab, or mirikizumab 2

   • Newer agents with strong efficacy data

Dosing Considerations:

• Extended induction regimens (up to 16 weeks) or dose escalation may be beneficial, particularly in severe disease 2
• For vedolizumab specifically: Some patients respond slowly; however, if no improvement by Week 14, discontinue 3

Addressing Specific Symptoms

Bloody Stool, Diarrhea, Abdominal Pain

• These indicate active colonic inflammation requiring therapy escalation as above
• Stop 5-ASA medications if currently taking them—no benefit when on advanced therapy 1

Heartburn and Nausea/Vomiting

• May represent:
  • Upper GI inflammation (less common in UC)
  • Medication side effects from vedolizumab 3
  • Concurrent gastroesophageal reflux disease
• Add proton pump inhibitor for heartburn
• Consider antiemetics (ondansetron, metoclopramide) for nausea/vomiting
• If symptoms persist after UC treatment optimization, pursue upper endoscopy

Constipation Alternating with Diarrhea

• Suggests proximal constipation with overflow diarrhea OR
• Distal proctitis causing rectal spasm
• Requires flexible sigmoidoscopy/colonoscopy to assess disease extent and severity
• May need topical therapy (mesalamine or corticosteroid enemas/suppositories) as adjunct

Monitoring and Safety Considerations

Before Switching Therapy:

1. Obtain objective measures:

   • Fecal calprotectin or lactoferrin
   • CRP, CBC, comprehensive metabolic panel
   • Stool studies (C. difficile, enteric pathogens, CMV if severe)
   • Endoscopy with biopsies to confirm active inflammation and rule out CMV colitis 3

2. Check vedolizumab drug levels and antibodies if available

   • Low levels may indicate need for dose optimization rather than switching
   • However, subcutaneous vedolizumab 108 mg every 2 weeks is an option if on IV therapy 3

3. Screen for infections before escalating:

   • Tuberculosis (QuantiFERON or PPD)
   • Hepatitis B and C
   • HIV (if risk factors)

Vedolizumab Safety Profile:

Vedolizumab has favorable safety compared to other biologics 4, 5:

• Infusion reactions <5% 4
• No increased serious infection risk vs. placebo in trials 3, 4
• No cases of progressive multifocal leukoencephalopathy 4
• Rare hepatotoxicity (monitor LFTs) 3

Common Pitfalls to Avoid

1. Don't continue ineffective therapy: If no response by Week 14 on vedolizumab, switch 3
2. Don't add 5-ASA to advanced therapy: No additional benefit and increases pill burden 1
3. Don't use thiopurine or methotrexate monotherapy for active disease 2, 1
4. Don't delay endoscopy: Objective assessment prevents treating symptoms without confirmed inflammation
5. Don't miss CMV colitis: Can mimic UC flare; requires antiviral therapy, not immunosuppression escalation
6. Don't use high-dose IV steroids (>60 mg/day): No additional benefit 1

Recommended Treatment Plan

For this patient, the optimal approach is:

1. Immediate: Obtain stool studies, inflammatory markers, and schedule urgent flexible sigmoidoscopy
2. If moderate disease confirmed: Switch to infliximab (preferred for faster onset) or ustekinumab (effective post-vedolizumab failure) 2, 1
3. Consider combination therapy: Add thiopurine or methotrexate to TNF antagonist for enhanced efficacy 2, 1
4. Symptomatic management: PPI for heartburn, antiemetics for nausea, assess for functional overlay
5. If severe/hospitalized: IV methylprednisolone 40-60 mg/day, then infliximab if steroid-refractory 1

The 2024 AGA guidelines provide strong recommendations for multiple advanced therapies after vedolizumab failure, with infliximab, ustekinumab, and JAK inhibitors being the most evidence-based options 2.